Welcome to our dedicated page for Phathom Pharmaceuticals news (Ticker: PHAT), a resource for investors and traders seeking the latest updates and insights on Phathom Pharmaceuticals stock.
Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) is a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, and its news flow reflects this GI specialization. Company updates frequently center on VOQUEZNA (vonoprazan), a first-in-class potassium-competitive acid blocker (PCAB) that Phathom markets in the United States for adult patients with Erosive GERD, Non-Erosive GERD, and Helicobacter pylori infection in combination regimens.
Investors and healthcare observers following PHAT news can expect regular announcements on commercial performance, including prescription milestones and revenue updates tied to VOQUEZNA tablets, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Phathom’s press releases have highlighted metrics such as total VOQUEZNA prescriptions dispensed in the United States and quarterly financial results, often accompanied by commentary on commercialization strategy and expense trends.
Another major category of Phathom news involves clinical and scientific developments. The company reports progress in trials like the Phase 3 pHalcon-NERD-301 study in Non-Erosive GERD and the Phase 2 pHalcon-EoE-201 study evaluating VOQUEZNA in eosinophilic esophagitis. Publications in peer-reviewed journals and presentations at gastroenterology conferences, such as the American College of Gastroenterology Annual Scientific Meeting, are common topics in its releases.
Phathom also issues news on capital markets activity, including proposed and priced underwritten public offerings of common stock and pre-funded warrants, as well as corporate updates such as leadership appointments and participation in investor conferences. Together, these news items provide a view into the company’s GI-focused strategy, clinical pipeline, commercial trajectory, and financing plans. For users tracking PHAT, the news page offers a consolidated stream of these developments over time.
Phathom Pharmaceuticals (Nasdaq: PHAT) has appointed Dr. James Topper to its Board of Directors. Dr. Topper, Managing Partner at Frazier Life Sciences, returns after previously serving on Phathom's board from 2018 to 2021. His extensive experience includes investments in over 35 biopharma companies and leadership roles in renowned organizations. This appointment comes as Phathom transitions from a clinical-stage to a commercial entity, aiming to launch its products in the first quarter of next year.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference. The management team's on-demand presentation will be available starting September 12, 2022, at 7:00 a.m. ET. The conference runs from September 12-14, and management will also engage in one-on-one meetings. Phathom is focused on novel treatments for gastrointestinal diseases, including its lead product, vonoprazan, which is approved for H. pylori treatment and has an FDA review pending for erosive esophagitis.
Phathom Pharmaceuticals (PHAT) has achieved significant milestones, including the FDA's acceptance of its New Drug Application for vonoprazan in erosive esophagitis (EE), with a PDUFA date set for January 11, 2023. This follows the approval of VOQUEZNA DUAL and TRIPLE PAK for H. pylori infections. Despite detecting trace nitrosamine levels, the company is collaborating with the FDA to ensure compliance and aims for a combined product launch in Q1 2023. The Q2 2022 financial results showed a net loss of $50.9 million, while R&D expenses decreased to $18.8 million.
Phathom Pharmaceuticals (Nasdaq: PHAT) will participate in a fireside chat at the Jefferies Healthcare Conference on June 8, 2022, at 1:30 p.m. ET. Management will also engage in one-on-one meetings throughout the conference, which runs from June 8-10, 2022. The live webcast and archived recording of the chat will be accessible via the Phathom website for 90 days post-event. Phathom is focused on novel gastrointestinal treatments and has exclusive rights to vonoprazan for H. pylori infection and is awaiting FDA review for erosive esophagitis treatment.
On May 25, 2022, Phathom Pharmaceuticals (Nasdaq: PHAT) announced the FDA's acceptance of its New Drug Application for vonoprazan, targeting erosive esophagitis (EE) and heartburn relief in adults. This application, assigned a standard review, has a PDUFA action date of January 11, 2023. Vonoprazan is a first-in-class potassium-competitive acid blocker, representing the first significant GERD treatment innovation in over 30 years. The application is backed by positive Phase 3 trial results, indicating potential to meet unmet patient needs.
Phathom Pharmaceuticals (Nasdaq: PHAT) presented significant data on vonoprazan at Digestive Disease Week 2022, demonstrating its effectiveness against erosive esophagitis (EE). The Phase 3 PHALCON-EE trial found vonoprazan achieved 92.9% healing by week 8, outperforming lansoprazole (84.6%). At week 24, 80.7% of patients maintained healing with vonoprazan compared to 72.0% with lansoprazole. Additionally, vonoprazan showed superior acid suppression and presented promising data regarding Helicobacter pylori treatment patterns in the U.S., indicating the need for improved management. These findings strengthen vonoprazan's potential in treating EE.
Phathom Pharmaceuticals (Nasdaq: PHAT) announced new investigational data regarding vonoprazan for treating erosive esophagitis (EE) at Digestive Disease Week® (DDW) 2022. The findings reveal real-world evidence highlighting unmet treatment needs for H. pylori infections. Phathom's research received multiple 'posters of distinction' recognition from the American Gastroenterological Association. Notable presentations include Phase 3 results of vonoprazan as monotherapy, demonstrating promising efficacy compared to traditional proton pump inhibitors. The conference takes place from May 21-24 in San Diego, CA.
Phathom Pharmaceuticals (PHAT) announced FDA approval for its VOQUEZNA™ TRIPLE PAK and DUAL PAK for treating H. pylori infections in adults. This marks a significant regulatory milestone for the company. Additionally, it secured a revenue interest financing agreement of up to $260 million, providing a strong capital foundation without diluting shareholder equity. Financial results for Q1 2022 reflect a net loss of $40.7 million, an increase from $34.8 million in Q1 2021, indicating ongoing investment in commercial launch and R&D while reducing expenses in certain areas.
Phathom Pharmaceuticals (Nasdaq: PHAT) has secured a revenue interest financing agreement of up to $260 million, including a $100 million upfront payment and $160 million contingent upon FDA approval of vonoprazan for erosive esophagitis (EE). This financing will support the launch of vonoprazan for H. pylori and EE and fund ongoing Phase 3 trials. Investors will receive a 10% royalty on net sales, capped at 2.0x the total payments. Phathom anticipates sufficient capital to fund operations through 2024.
Phathom Pharmaceuticals (NASDAQ: PHAT) has received FDA approval for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK, innovative treatment regimens for Helicobacter pylori infection in adults. These regimens, which include vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), show superior eradication rates compared to traditional lansoprazole-based therapies. The launch is anticipated in Q3 2022, providing two options, including a clarithromycin-free regimen, addressing declining eradication rates among the 115 million affected U.S. patients.